CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 09/12/2025 GMT			5-day change	1st Jan Change
185.99 ^USD	-0.60%		+6.43%	+0.75%

12-03	Charles River Laboratories International, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:00 AM
12-03	Charles River Laboratories International Inc - DSA Net Book-to-Bill Improved Each Month Since Q3 2025 - SEC Filing	RE

Charles River Laboratories International, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:00 AM	12-03
Charles River Laboratories International Inc - DSA Net Book-to-Bill Improved Each Month Since Q3 2025 - SEC Filing	12-03	RE
Jefferies Adjusts PT on Charles River Laboratories International to $205 From $200, Maintains Buy Rating	12-02	MT
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS	12-01	PR
Charles River Laboratories to Present at Evercore Healthcare Conference	12-01	BU
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL	11-24	BU
Charles River Laboratories International, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 11:30 AM	11-18
Argus Upgrades Charles River Laboratories International to Buy From Hold, Price Target is $200	11-17	MT
Charles River Laboratories International Inc - SEC concludes investigation, no action against Charles River Labs - SEC filing	11-17	RE
Charles River Laboratories to Present at Jefferies Global Healthcare Conference	11-17	BU
Morgan Stanley Adjusts Charles River Laboratories International PT to $185 From $170, Maintains Equal Weight Rating	11-11	MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $197 From $205	11-10	MT
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL	11-08	PR
The Market Can't Make Up Its Mind	11-06
JPMorgan Adjusts Price Target on Charles River Laboratories International to $165 From $160, Maintains Neutral Rating	11-06	MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $200 From $195, Maintains Buy Rating	11-06	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $195, Maintains Overweight Rating	11-06	MT
Baird Upgrades Charles River Laboratories International to Outperform From Neutral, Adjusts PT to $199 From $178	11-06	MT
Charles River Laboratories International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 27, 2025	11-05	CI
Charles River Laboratories International, Inc., Q3 2025 Earnings Call, Nov 05, 2025	11-05
Charles River Laboratories to Sell Underperforming, Non-Core Businesses	11-05	MT
Charles River Laboratories International, Inc. Revises Earnings Guidance for the Year 2025	11-05	CI
Charles River Laboratories International, Inc. announces an Equity Buyback for $1,000 million worth of its shares.	11-05	CI
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	11-05	CI
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	11-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Filters